Sitemap
Pages
- Accelerate MRD Testing
- Biobank Repository
- Clinical Lab Services – Internationally Standardized Testing – LabPMM
- Company – Experts in Molecular Products and Services For Oncology Testing
- Conferences
- Contact Us – Generating Clinically Actionable Results That Optimize Treatments
- Diseases – Lymphoid & Myeloid Diagnostic Solutions
- Hematological Testing Guide
- (MALT lymphoma)
- Acute leukemias of ambiguous lineage
- Acute myeloid leukemia (AML) and related neoplasms
- Acute Promyelotic Leukemia (APL)
- Adult T-cell leukemia/lymphoma
- Anaplastic large-cell lymphoma
- Angioimmunoblastic T-cell lymphoma
- B-lymphoblastic leukemia/lymphoma
- Blastic plasmacytoid dendritic cell neoplasm
- Chronic lymphocytic leukemia (CLL)
- Chronic myeloid leukemia (CML)
- classical Hodgkin lymphoma
- Diffuse large B-cell lymphoma (DLBCL), NOS
- Essential thrombocythemia (ET)
- Follicular lymphoma
- Follicular T-cell lymphoma*
- Hairy cell leukemia
- Histiocytic and dendritic cell neoplasms
- Hodgkin lymphoma
- Mantle cell lymphoma (MCL)
- Marginal zone lymphoma
- Mature B-cell neoplasms
- Mature T and NK neoplasms
- Monoclonal gammopathy of undetermined significance (MGUS)
- Mycosis fungoides
- Myelodysplastic syndromes (MDS)
- Myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
- Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2
- Myeloproliferative neoplasms (MPN)
- Peripheral T-cell lymphoma
- Plasma cell myeloma (Multiple Myeloma)
- Polycythemia vera (PV)
- Posttransplant lymphoproliferative disorders (PTLD)
- Primary myelofibrosis (PMF)
- S ´ezary syndrome
- small lymphocytic lymphoma (SLL)
- Suspect B-cell Proliferations
- T-Cell Large Granular Lymphocytic Leukemia (T-LGL Leukemia)
- T-Cell Prolymphocytic Leukemia (T-PLL)
- T-lymphoblastic leukemia/lymphoma
- Waldenstrom macroglobulinemia
- Hematological Testing Guide
- Diseases – Lymphoid Overview
- Diseases – Myeloid Overview
- FAQ
- Grant Application
- Home
- Legal Notices
- LeukoStrat MRD Solutions ( draft )
- LymphoTrack MRD Solutions
- LymphoTrack® Software Error Codes
- LymphoTrack® Software FAQs
- Mission, Vision, & Values – HR DRAFT
- MRD Clonality
- MRD Overview
- MRD Portfolio
- MRD Software Help
- Multiparametric Flow Cytometry Overview Page 2024
- Newsroom – Best in Class Assays, Reagents and Clinical Lab Services
- NGS Grant
- Old Videos
- Partnerships – Proven Strategies to Accelerate Drug Approvals
- Personalized Medicine
- PrepQuant
- Press Releases
- Privacy Policy
- Product & Service Catalogs
- Products – ABI Fluorescence Detection
- Products – Best-In-Class Assays & Reagents
- Publications – Pioneering The Molecular Diagnostic Field
- Science – Molecular Diagnostics and Personalized Molecular Medicine
- Software Terms and Conditions
- Terms and Conditions
- Web Privacy Policy
Posts
- AMP
Comparing DNA Extraction Methods for the LymphoTrack® IVD TRG Assay - AMP
Evaluation of An Alternative Fragmentation Method in High Throughput NGS Sample Testing of Minimal Residual Disease in Hematological Malignancies - AMP
Validation of an NGS based assay for monitoring FLT3 ITD and TKD variants in AML subjects - AMP
A Next-Generation Sequencing Based Analysis of Clonality across 39 Subjects Treated for Lymphoproliferative Disorders Reveals Matching Clones in the Diverse IGH Locus - ASH
End of Treatment Peripheral Blood TCR Evaluation for Minimal Residual Disease Evaluation in Peripheral T-cell Lymphomas - EHA
TRG Clonality Interrogation by CE and NGS: Bridging the Gap Between Classical and Leading Edge Technologies - 15th JSH International Symposium
- 15th World CB & CDx Summit Europe
- 26th JSLH
- 32nd Japanese Society for Gene Diagnosis and Therapy
- A Comprehensive Solution for AML Precision Diagnostics
- A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations
- A Practical Approach to Diagnostic Ig/TCR Clonality Evaluation in Clinical Pathology
- A Small Case Series of Intravascular Large B-Cell Lymphoma with Unexpected Findings: Subset of Cases with Concomitant Extravascular Central Nervous System (CNS) Involvement Mimicking Primary CNS Lymphoma
- A Streamlined Laboratory Workflow for Controlling Antibody and Reagent Lots on a 12C Flow Cytometry System
- A Systematic, Evidence-Based Workflow for Classifying KMT2A Fusions in AML
- AACR
- ADLM
- AMP
- AMP 2019 Video Series Part 1 of 4
- AMP 2019 Video Series Part 2 of 4
- AMP 2019 Video Series Part 3 of 4
- AMP 2019 Video Series Part 4 of 4
- AMP Global 2019 Video Series Part 1 of 4
- AMP Global 2019 Video Series Part 2 of 4
- AMP Global 2019 Video Series Part 3 of 4
- AMP Global 2019 Video Series Part 4 of 4
- AMP Middle East
- Application of cost–effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia
- Artificial Intelligence (AI) and other Data Science Applications in Molecular Pathology
- ASCO
- ASGCT
- ASH
- Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing
- Assessment of MRD by NGS in Daily Clinical Management of Multiple Myeloma
- Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment
- Bio-Europe Spring
- Breast Implant-Associated Anaplastic Large Cell Lymphoma: Two Distinct Clinicopathological Variants with Different Outcomes
- BSH
- CGC
- Classification of intestinal T‐cell receptor repertoires using machine learning methods can identify patients with coeliac disease regardless of dietary gluten status
- Clinical Utility of NGS in Lymphoid Malignancies
- Clinical Utility of NGS in Lymphoid Malignancies including Minimal Residual Disease (MRD) testing
- Clinical-scale Rapid Autologous BK-virus Specific T Cell Line generation from Kidney Transplant Recipients with Active Viremia for Adoptive Immunotherapy
- Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Clonality and Measurable Residual Disease (MRD) Testing on the Illumina NextSeq Sequencers
- Clonality Of Multiple Distinct Lymphoproliferative Disorders Occurring Within Individual HIV+ Patients
- Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications
- Comparing Data Generated Using Multiparametric Flow Cytometry, Capillary Electrophoresis, and Next-Generation Sequencing in a Cohort of B-Cell Lymphoproliferative Disorder Samples
- Comparison of Complete Genomics DNBSEQ-G99 Sequencer and Illumina® MiSeqTM using Invivoscribe’s FLT3 ITD MRD Assay and NPM1 MRD Assay
- Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
- Complementary Value of MRD Assessments by NGS and MFC for the Study of Hematologic Malignancies
- Corporate Overview
- Critical Mistakes to Avoid when Developing a Drug/CDx Combination for International Registrations
- Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas
- Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia
- Development and Implementation of an Automated and Highly Accurate Reporting Process for NGS-based Clonality Testing
- Diagnostic Utility of a Clonality Test for Lymphoproliferative Diseases in Koreans Using the BIOMED-2 PCR Assay
- Discordant Lymphoma Consisting of Mediastinal Large B-Cell Lymphoma and Nodular Sclerosis Hodgkin Lymphoma in the Right Supraclavicular Lymph Nodes: A Case Report
- DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant
- Dried Blood Spot Sampling for Detection of Monoclonal Immunoglobulin Gene Rearrangement
- ECP
- EHA
- EHA 47th JSTCT
- EHA Balkan Day
- ESMO
- Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms
- EU Notified Body (BSI Netherlands) and the EMA Grant Approval of the LeukoStrat® CDx FLT3 Mutation Assay for VANFLYTA® Therapy in the EU and EEA
- EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations
- Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal residual disease detection in Chinese patients with multiple myeloma
- Evaluation of Somatic Hypermutation Status in Chronic Lymphocytic Leukemia (CLL) in the Era of Next Generation Sequencing
- Evaluation of the polymerase chain reaction–based T-cell receptor β clonality test in the diagnosis of early mycosis fungoides
- Explore the Benefits, Considerations, and Utility of NGS B- and T-cell Clonality
- FDA approves new combination treatment for acute myeloid leukemia
- Feasibility of cell-free DNA collection and clonal immunoglobulin sequencing in South African patients with HIV-associated lymphoma
- From prognostication to precision in acute myeloid leukemia
- Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype
- German Supreme Court Upholds and Strengthens Invivoscribe FLT3 Patent Position
- Global Standardization of Flow Cytometry Results with AI Systems
- High-Throughput Sequencing of TCR Gene Rearrangements as a Useful Tool for Identifying and Tracking Minimal/Measurable Residual Disease (MRD) in Lymphoid Malignancies
- Hitachi High-Tech and Invivoscribe partner to advance molecular diagnostics and precision medicine
- Hydroa Vacciniforme-like Lymphoma: A Chronic EBV+ Lymphoproliferative Disorder with Risk to Develop a Systemic Lymphoma
- ICCS
- ICML
- Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patients
- IMGT/GeneInfo: T cell receptor gamma TRG and delta TRD genes in database give access to all TR potential V(D)J recombinations
- IMGT/JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V–J and V–D–J JUNCTIONs
- Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy
- Immunoblastic Follicular Lymphoma: A Very Unusual Transformation of Low-Grade Follicular Lymphoma
- Immunoglobulin gene rearrangement in Koreans with multiple myeloma: Clonality assessment and repertoire analysis using next-generation sequencing
- Immunoglobulin Heavy Chain High-Throughput Sequencing in Pediatric B-Precursor Acute Lymphoblastic Leukemia: Is the Clonality of the Disease at Diagnosis Related to Its Prognosis?
- Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia
- In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis
- Innovations in MRD Detection: Leveraging NGS to Gain Insights into Multiple Myeloma and B-ALL
- Invivoscribe – EHA 2019: Part 1 of 3
- Invivoscribe – EHA 2019: Part 2 of 3
- Invivoscribe – EHA 2019: Part 3 of 3
- Invivoscribe – ASCO – LeukoStrat CDx FLT3 Mutation Assay
- Invivoscribe Announces a Regional “Center of Excellence” Reference Laboratory in Beirut to Offer Specialized Gene Panels
- Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United States
- Invivoscribe Announces FDA Approval of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with FLT3-ITD Positive AML for Treatment with VANFLYTA
- Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Assay
- Invivoscribe Announces Key Submission in the EU, Expanded Presence and Activity in China
- Invivoscribe Announces Long-Term Collaboration Agreement with Illumina and Plans Release of NGS-based IVD Assay Kits
- Invivoscribe Announces Long-Term Collaboration to Develop Immuno-Oncology Tests With Thermo Fisher Scientific
- Invivoscribe Announces Registration of the LeukoStrat® CDx FLT3 Mutation Assay in the United Kingdom and Switzerland
- Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan
- Invivoscribe Appoints Masato Sasaki as General Manager of LabPMM, GK (Japan)
- Invivoscribe Diagnostic Technologies (Shanghai) Co. Ltd. Receives CAP Accreditation to Support Clinical Research Testing for Pharmaceutical Partners in China
- Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignancies
- Invivoscribe Expands Business into Solid Tumors with Assays and Services to Identify and Monitor CAR-T and TCR Immuno-Therapies
- Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial
- Invivoscribe Expands Ion PGM NGS Platform Menu: Releases Additional CE-IVD Clonality Kits with Bioinformatics Software and RUO Kits with MRD Software
- Invivoscribe Expands Long-Term Collaboration Agreement to Release FLT3 Mutation and Clonality Assay Kits
- Invivoscribe files sPMA with the FDA for use of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with Newly Diagnosed FLT3-ITD Positive AML
- Invivoscribe Launches Grant Program to Support Novel Applications for Sequence-Based Analyses of the Immune System
- Invivoscribe Launches LeukoStratKMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide
- Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer Research
- Invivoscribe Premieres 12-Color Flow Cytometry Capabilities at their Reference Labs in the US, Europe, and China
- Invivoscribe Submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to Support Daiichi Sankyo Submissions for Quizartinib
- Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners.
- Invivoscribe Submits Pre-Market Approval Application in Japan and Panel Track Supplement in the US to Screen Acute Myeloid Leukemia (AML) Patients for FLT3 Mutations
- Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japan
- Invivoscribe to Exhibit at 25th EHA Annual Congress
- Invivoscribe to Participate in Virtual ASCO 2020
- Invivoscribe To Present At Biotech Showcase™ 2019 In San Francisco
- Invivoscribe’s LabPMM Gains New York State Approval for the FLT3 ITD MRD Assay
- Invivoscribe® Receives Approval in Japan for its LeukoStrat® CDx FLT3 Mutation Assay to Assess Acute Myeloid Leukemia (AML) Patients Eligible for Treatment with Xospata® (gilteritinib fumarate)
- Invivoscribe® Receives FDA Approval for the LeukoStrat® CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt® and is the First Companion Diagnostic for AML
- Invivoscribe® Releases LeukoStrat® CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit.
- Invivoscribe® Releases LymphoTrack® TRB Assay on MiSeq® and LymphoTrack® Minimal Residual Disease (MRD) Software
- Ion Torrent Developers Alliance Program Designed to Speed Targeted NGS Assay Development
- JACLaS
- JAMT
- Japan’s MHLW Approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD AML. Expands Use to Include Specimens Collected in EDTA
- JCA Annual Meeting
- JSH Annual Meeting
- JSMO 2025
- JSPHO Annual Meeting
- Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AML
- Lab Secrets: Stratification and Prognoses of Leukemia and Multiple Myeloma using Next-Generation Sequencing (NGS)
- Lab Secrets: The Potential for NGS-based MRD Testing for Acute Lymphoblastic Leukemia – The Austin Experience
- LabPMM Receives New York State Approval for the NPM1 MRD Assay – Informing Therapy and Accelerating Targeted Trials
- Level Up Your MRD Testing: Leveraging Standardized & Sensitive AML Assessments
- Leveraging Highly Sensitive NGS Assays for Clonality, SHM and MRD Assessments
- Leveraging Highly Sensitive NGS FLT3-ITD and NPM1 MRD Assessments in AML
- Leveraging Standardized MRD Assays to Guide CLL Treatment
- LymphoTrack Is Equally Sensitive as PCR GeneScan and Sanger Sequencing for Detection of Clonal Rearrangements in ALL Patients
- Machine Learning Algorithms Accelerate Throughput of a Flow – Sequencing Cell Based Assay for an Acute Myeloid Leukemia (AML) Therapeutic Discovery Platform
- Measurable residual disease and post-transplantation gilteritinib maintenance for patients with FLT3 ITD mutated AML
- Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia
- Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia
- Medica
- Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)
- Minimal/Measurable Residual Disease (MRD) Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor
- Molecular Diagnostics of Hematologic Malignancies
- Molecular Genetic Data Favoring a Sequential Clonal Transformation of a Large B Cell Lymphoma into an Anaplastic Large T Cell Lymphoma, ALK-Negative
- Molecular pathology diagnosis of diffuse large B cell lymphoma using BIOMED-2 clonal gene rearrangements
- Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients
- Monitoring minimal residual disease in the bone marrow using next generation sequencing
- MPAICON
- MRD Applications and Analysis
- Mucosal CD30-Positive T-Cell Lymphoproliferative Disorder Arising in the Oral Cavity Following Dental Implants
- Multiparameter Approach to CLL Diagnosis, Prognostic Biomarker Assessment, and MRD Monitoring
- Multiple Clonal Ig/TCR Products: Implications for Interpretation of Clonality Findings
- New Frontiers in Hematology: From CLL Tumor Precursor Cells to Tracking Disease Burden in Multiple Myeloma
- Next-generation sequencing of immunoglobulin genes in lymphoid malignancies
- NGS Analysis of Clonality and Minimal Residual Disease in a Patient with Concurrent Richter’s Transformation and CLL/SLL
- NGS Assessment of SHM in CLL/SLL: A Practical Comparison of Platforms and Primers
- NGS-based Clinical Assessment of B- and T-cell Clonality and MRD Determination
- Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis
- Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutations
- Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)
- NOW AVAILABLE! MRD solutions for B- and T-cell clonality tracking
- Paediatric and Adolescent Elevated Conjunctival Lesions in the Plical Area: Lymphoma or Reactive Lymphoid Hyperplasia?
- Performance Comparison of Illumina® MiSeq™ and MiSeq™ i100 Systems using Invivoscribe’s LymphoTrack® Assays
- Performance Comparison of Invivoscribe’s LymphoTrack® Assays Between Complete Genomics DNBSEQ-G99 and Illumina® MiSeqTM NGS Platforms
- Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patients
- Plan for a Successful International Drug Approval with Early Development of the Accompanying CDx
- Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a “Spike-in” Clonal Sequence
- Plasticity of the human IgM repertoire in response to long‐term spaceflight
- Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
- Precision Med Tri-Con
- Primary non-Hodgkin lymphoma of the tongue base: the clinicopathology of seven cases and evaluation of HPV and EBV status
- Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms
- Quantitation of CMV Specific T-Cell Expansion Using T Cell Receptor Beta Locus Deep Sequencing to Identify Patients at Risk of Viral Complications
- QuANTUM-First: Clinical Validation of the LeukoStrat Companion Diagnostic for the Selection of Patients With Acute Myeloid Leukemia Harboring FMS-Like Tyrosine Kinase 3–Internal Tandem Duplications for Treatment With Quizartinib
- Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma
- Review of Guidelines for Interpreting Somatic Hypermutation Status in Chronic Lymphocytic Leukemia in the Era of High-Throughput Sequencing
- Roswell Park Comprehensive Cancer Center Licenses Invivoscribe’s LymphoTrack Software for Plug and Play Pipeline Use
- Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing
- Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL
- SOHO
- Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma
- Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma
- Study Suggests Critical Link Between Residual FLT3-ITD Mutations in Remission and Post-Transplant Outcomes in AML
- T and B cell clonal expansion in Ras associated lymphoproliferative disease (RALD) as revealed by next generation sequencing
- Targeted Deep Sequencing Reveals Clinically Relevant Subclonal IgHV Rearrangements in Chronic Lymphocytic Leukemia
- The 48th Annual Meeting of the Molecular Biology Society of Japan
- The 65th Annual Meeting of the Japanese Society of Lymphoma Research & Hematopathology
- The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, including the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay
- The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies
- The Evolving Role of NGS and Measurable Residual Disease in CLL/SLL and AML
- Unlocking the Potential of NGS Clonality and MRD Testing: From Research to High-Throughput Environments – Part 01
- Unlocking the Potential of NGS Clonality and MRD Testing: From Research to High-Throughput Environments – Part 02
- Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma
- US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the US
Invivoscribe also Receives National Reimbursement for CDx Assay in Japan - USCAP
- Validation and interpretation of IGH and TCR clonality testing by Ion Torrent S5 NGS for diagnosis and disease monitoring in B and T cell cancers
- Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing
- VIRTUAL EHA: Clonality analysis with NGS is the new frontier in MRD detection
- VIRTUAL EHA: Incorporating NGS Methods for Routine Clonality Assessment and Disease Monitoring of Lymphoid Malignancies
- VIRTUAL EHA: Next Generation Analysis in CLL and Other Malignancies
- We are Invivoscribe – Company Overview
Products
- Dad hat
- Invivoscribe – Beach Towel (Version 01)
- Invivoscribe – Beach Towel (Version 02)
- Invivoscribe – Beach Towel (Version 03)
- Invivoscribe – Cuffed Beanie (Version 01)
- Invivoscribe – Hat (Version 01)
- Invivoscribe – Hat (Version 02)
- Invivoscribe – iPhone Case (Version 01)
- Invivoscribe – iPhone Case (Version 02)
- Invivoscribe – Laptop Sleeve (Version 01)
- Invivoscribe – Laptop Sleeve (Version 02)
- Invivoscribe – Men’s Embroidered Polo Shirt (Version 01)
- Invivoscribe – Minimalist Backpack (Navy)
- Invivoscribe – Minimalist Backpack (Royal)
- Invivoscribe – Navy Blue Distressed Vintage Hat
- Invivoscribe – Navy Blue Unisex Hoodie
- Invivoscribe – Navy Blue Unisex T-Shirt
- Invivoscribe – Premium Face Mask (Navy)
- Invivoscribe – Premium Face Mask (Royal)
- Invivoscribe – Samsung Case (Version 01)
- Invivoscribe – Samsung Case (Version 02)
- Invivoscribe – Snapback Hat (Royal/Navy)
- Invivoscribe – Throw Blanket (Version 01)
- Invivoscribe – Throw Blanket (Version 02)
- Invivoscribe – Trucker Cap (Version 01)
- Invivoscribe – Trucker Cap (Version 02)
- Invivoscribe – Unisex Hoodie (Navy)
- Invivoscribe – Unisex Long Sleeve Shirt
- Invivoscribe – Vintage Cotton Twill Cap (Version 01)
- Invivoscribe – Women’s Athletic T-Shirt
- Invivoscribe – Women’s Embroidered Polo Shirt (Version 01)
- Invivoscribe – Women’s Joggers (Version 01)
- Mouse pad
- Mug
